The Oncologist, Vol. 11, No. 3, 274-284, March 2006; doi:10.1634/theoncologist.11-3-274
© 2006 AlphaMed Press
Combining Targeted Therapies and Drugs with Multiple Targets in the Treatment of NSCLC
Paolo Maionea,
Cesare Gridellia,
Teresa Troianib,
Fortunato Ciardiellob
a Division of Medical Oncology, "S.G. Moscati" Hospital, Avellino, Italy;
b Second University of Naples, Naples, Italy
Key Words. NSCLC • Multitargeted therapy • Erlotinib • Bevacizumab • ZD6474
Correspondence:
Paolo Maione, M.D., Division of Medical Oncology, "S.G. Moscati" Hospital, Contrada Amoretta, 83100 Avellino, Italy. Telephone: 39-0825-203573; Fax: 39-0825-203556; e-mail: pmaione{at}libero.it.
The first generation of clinical trials of targeted agents in non-small cell lung cancer (NSCLC) treatment has concluded. To date, only a few of these new agents can offer hope of a substantial impact on the natural history of the disease. Nevertheless, clinically meaningful advances have already been achieved. In chemotherapy-refractory advanced NSCLC patients, gefitinib and erlotinib, two epidermal growth factor receptor tyrosine kinase inhibitors, represent a further chance for tumor control and symptom palliation. In chemotherapy-naive, advanced, nonsquamous NSCLC patients, the combination of the antivascular endothelial growth factor monoclonal antibody bevacizumab with chemotherapy was demonstrated to produce better survival outcomes than with chemotherapy alone. The relative failure of first-generation targeted therapies in lung cancer may be a result of multilevel cross-stimulation among the targets of the new biological agents. Thus, blocking only one of these pathways allows others to act as salvage or escape mechanisms for cancer cells. Preclinical evidence of the synergistic antitumor activity achievable by combining targeted agents that block multiple signaling pathways has recently been emerging. Clinical trials of multitargeted therapy may represent the second generation of studies in this field, and some of these are already ongoing. In a recent phase I/II trial, the combination of erlotinib and bevacizumab demonstrated very promising activity in the treatment of advanced NSCLC pretreated with chemotherapy. Whether the multitargeted approach is best performed using combinations of selective agents or agents that intrinsically target various targets is a matter of debate.
This article has been cited by other articles:

|
 |

|
 |
 
A. Bozec, A. Sudaka, N. Toussan, J.-L. Fischel, M.-C. Etienne-Grimaldi, and G. Milano
Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model
Ann. Onc.,
October 1, 2009;
20(10):
1703 - 1707.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Schettino, M. A. Bareschino, A. Rossi, P. Maione, V. Castaldo, N. Mazzeo, P. C. Sacco, M. L. Ferrara, G. Palazzolo, F. Ciardiello, et al.
Review: The potential role of bevacizumab in early stages and locally advanced non-small cell lung cancer
Therapeutic Advances in Medical Oncology,
July 1, 2009;
1(1):
5 - 13.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
A. C. Klimowicz, S. A. Bisson, K. Hans, E. M. Long, H. C. Hansen, and S. M. Robbins
The phytochemical piceatannol induces the loss of CBL and CBL-associated proteins
Mol. Cancer Ther.,
March 1, 2009;
8(3):
602 - 614.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Fichtner, J. Rolff, R. Soong, J. Hoffmann, S. Hammer, A. Sommer, M. Becker, and J. Merk
Establishment of Patient-Derived Non-Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers
Clin. Cancer Res.,
October 15, 2008;
14(20):
6456 - 6468.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. L. Boehm, M. Sen, R. Seethala, W. E. Gooding, M. Freilino, S. M. Y. Wong, S. Wang, D. E. Johnson, and J. R. Grandis
Combined Targeting of Epidermal Growth Factor Receptor, Signal Transducer and Activator of Transcription-3, and Bcl-XL Enhances Antitumor Effects in Squamous Cell Carcinoma of the Head and Neck
Mol. Pharmacol.,
June 1, 2008;
73(6):
1632 - 1642.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-C. Wang, S. K. Kulp, D. Wang, C.-C. Yang, A. M. Sargeant, J.-H. Hung, Y. Kashida, M. Yamaguchi, G.-D. Chang, and C.-S. Chen
Targeting Endoplasmic Reticulum Stress and Akt with OSU-03012 and Gefitinib or Erlotinib to Overcome Resistance to Epidermal Growth Factor Receptor Inhibitors
Cancer Res.,
April 15, 2008;
68(8):
2820 - 2830.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Krol, R. E. Francis, A. Albergaria, A. Sunters, A. Polychronis, R. C. Coombes, and E. W.-F. Lam
The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells
Mol. Cancer Ther.,
December 1, 2007;
6(12):
3169 - 3179.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Gridelli, P. Maione, A. Rossi, and F. De Marinis
The Role of Bevacizumab in the Treatment of Non-Small Cell Lung Cancer: Current Indications and Future Developments
Oncologist,
October 1, 2007;
12(10):
1183 - 1193.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Zundelevich, G. Elad-Sfadia, R. Haklai, and Y. Kloog
Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid)
Mol. Cancer Ther.,
June 1, 2007;
6(6):
1765 - 1773.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Gridelli, P. Maione, F. Del Gaizo, G. Colantuoni, C. Guerriero, C. Ferrara, D. Nicolella, D. Comunale, A. De Vita, and A. Rossi
Sorafenib and Sunitinib in the Treatment of Advanced Non-Small Cell Lung Cancer
Oncologist,
February 1, 2007;
12(2):
191 - 200.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Ono and M. Kuwano
Molecular Mechanisms of Epidermal Growth Factor Receptor (EGFR) Activation and Response to Gefitinib and Other EGFR-Targeting Drugs
Clin. Cancer Res.,
December 15, 2006;
12(24):
7242 - 7251.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2006 by AlphaMed Press.
|
|